Protein arginine methyltransferases (PRMTs): Orchestrators of cancer pathogenesis, immunotherapy dynamics, and drug resistance
Authors:
- 10 February 2024
- journal article
- review article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 221, 116048
Abstract
No abstract availableKeywords
Funding Information
- Jilin University (2021YX0412)
This publication has 337 references indexed in Scilit:
- PRMT5 promotes ovarian cancer growth through enhancing Warburg effect by methylating ENO1Medcomm, 2023
- The PRMT6/PARP1/CRL4B Complex Regulates the Circadian Clock and Promotes Breast TumorigenesisAdvanced Science, 2023
- Role of tumor microenvironment in cancer progression and therapeutic strategyCancer Medicine, 2023
- Protein arginine methyltransferase 3 promotes glycolysis and hepatocellular carcinoma growth by enhancing arginine methylation of lactate dehydrogenase AClinical and Translational Medicine, 2022
- Splicing Regulator p54nrb/Non–POU Domain–Containing Octamer‐Binding Protein Enhances Carcinogenesis Through Oncogenic Isoform Switch of MYC Box–Dependent Interacting Protein 1 in Hepatocellular CarcinomaHepatology, 2019
- Protein arginine methyltransferase 5: A novel therapeutic target for triple‐negative breast cancersCancer Medicine, 2019
- Significant association of PRMT6 hypomethylation with colorectal cancerJournal of Clinical Laboratory Analysis, 2018
- Upregulation of PRMT6 by LPS suppresses Klotho expression through interaction with NF‐κB in glomerular mesangial cellsJournal of Cellular Biochemistry, 2017
- FGF Receptors: Cancer Biology and TherapeuticsMedicinal Research Reviews, 2013
- The tumour suppressor and chromatin‐remodelling factor BRG1 antagonizes Myc activity and promotes cell differentiation in human cancerEMBO Molecular Medicine, 2012